Brett Kaplan, MD, MBA is the Chief Financial Officer of Chroma Medicine, a biotechnology company focused on treatments for patients with genetically driven diseases. Previously, Brett was the Chief Financial Officer of Prevail Therapeutics, a gene therapy biotechnology company that was acquired by Eli Lilly. From August 2010 to November 2018, Dr. Kaplan worked at Evercore, an investment bank, where he most recently served as Managing Director. At Evercore he was involved in numerous strategic and financing transactions including advising Bristol-Myers Squibb on its acquisitions of Celgene and Amylin; Takeda on its acquisitions of Shire and of Ariad and Akebia on its merger with Keryx. Prior to Evercore, Dr. Kaplan was an Equity Research Analyst at Cowen and Company, an investment bank, from 2007 to 2010. Previously, Dr. Kaplan held business and marketing positions at Cubist Pharmaceuticals, Biopure Corporation, and Eli Lilly and Company. Dr. Kaplan received an MBBCh and an MBA from the University of Witwatersrand.